These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 22949875)

  • 41. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.
    Zecca L; Casella L; Albertini A; Bellei C; Zucca FA; Engelen M; Zadlo A; Szewczyk G; Zareba M; Sarna T
    J Neurochem; 2008 Aug; 106(4):1866-75. PubMed ID: 18624918
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.
    Sherer TB; Betarbet R; Stout AK; Lund S; Baptista M; Panov AV; Cookson MR; Greenamyre JT
    J Neurosci; 2002 Aug; 22(16):7006-15. PubMed ID: 12177198
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Redox proteomics in aging rat brain: involvement of mitochondrial reduced glutathione status and mitochondrial protein oxidation in the aging process.
    Perluigi M; Di Domenico F; Giorgi A; Schininà ME; Coccia R; Cini C; Bellia F; Cambria MT; Cornelius C; Butterfield DA; Calabrese V
    J Neurosci Res; 2010 Dec; 88(16):3498-507. PubMed ID: 20936692
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it.
    Fahn S; Cohen G
    Ann Neurol; 1992 Dec; 32(6):804-12. PubMed ID: 1471873
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 5-(3,4-Difluorophenyl)-3-(6-methylpyridin-3-yl)-1,2,4-oxadiazole (DDO-7263), a novel Nrf2 activator targeting brain tissue, protects against MPTP-induced subacute Parkinson's disease in mice by inhibiting the NLRP3 inflammasome and protects PC12 cells against oxidative stress.
    Xu LL; Wu YF; Yan F; Li CC; Dai Z; You QD; Jiang ZY; Di B
    Free Radic Biol Med; 2019 Apr; 134():288-303. PubMed ID: 30615919
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease.
    Golpich M; Amini E; Hemmati F; Ibrahim NM; Rahmani B; Mohamed Z; Raymond AA; Dargahi L; Ghasemi R; Ahmadiani A
    Pharmacol Res; 2015 Jul; 97():16-26. PubMed ID: 25829335
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease?
    Andersen JK
    Novartis Found Symp; 2001; 235():11-20; discussion 20-5. PubMed ID: 11280021
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson's disease.
    Milanese C; Cerri S; Ulusoy A; Gornati SV; Plat A; Gabriels S; Blandini F; Di Monte DA; Hoeijmakers JH; Mastroberardino PG
    Cell Death Dis; 2018 Jul; 9(8):818. PubMed ID: 30050065
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Neuronal death caused by apoptosis in Parkinson disease].
    Ruberg M; France-Lanord V; Brugg B; Lambeng N; Michel PP; Anglade P; Hunot S; Damier P; Faucheux B; Hirsch E; Agid Y
    Rev Neurol (Paris); 1997 Sep; 153(8-9):499-508. PubMed ID: 9683999
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Therapeutic Implications of Tea Polyphenols Against Dopamine (DA) Neuron Degeneration in Parkinson's Disease (PD).
    Zhou ZD; Xie SP; Saw WT; Ho PGH; Wang H; Lei Z; Yi Z; Tan EK
    Cells; 2019 Aug; 8(8):. PubMed ID: 31426448
    [No Abstract]   [Full Text] [Related]  

  • 51. Modulation of alpha-synuclein aggregation by dopamine: a review.
    Leong SL; Cappai R; Barnham KJ; Pham CL
    Neurochem Res; 2009 Oct; 34(10):1838-46. PubMed ID: 19444607
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Current views on the mechanisms of dopaminergic neuron death of the nigrostriatal system in Parkinson's disease].
    Bertrand E; Lechowicz W; Szpak GM; Dymecki J
    Neurol Neurochir Pol; 1997; 31(2):295-302. PubMed ID: 9380259
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oxygen free radicals and Parkinson's disease.
    Adams JD; Odunze IN
    Free Radic Biol Med; 1991; 10(2):161-9. PubMed ID: 2016074
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nuclear factor erythroid 2-related factor 2 signaling in Parkinson disease: a promising multi therapeutic target against oxidative stress, neuroinflammation and cell death.
    Kumar H; Koppula S; Kim IS; More SV; Kim BW; Choi DK
    CNS Neurol Disord Drug Targets; 2012 Dec; 11(8):1015-29. PubMed ID: 23244425
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
    Büeler H
    Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o'-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease.
    Pennathur S; Jackson-Lewis V; Przedborski S; Heinecke JW
    J Biol Chem; 1999 Dec; 274(49):34621-8. PubMed ID: 10574926
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of microgliosis, oxidative stress and associated neuroinflammation in the pathogenesis of Parkinson's disease: The therapeutic role of Nrf2 activators.
    Jayaram S; Krishnamurthy PT
    Neurochem Int; 2021 May; 145():105014. PubMed ID: 33689805
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bruceine D elevates Nrf2 activation to restrain Parkinson's disease in mice through suppressing oxidative stress and inflammatory response.
    Yang Y; Kong F; Ding Q; Cai Y; Hao Y; Tang B
    Biochem Biophys Res Commun; 2020 Jun; 526(4):1013-1020. PubMed ID: 32321640
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Copper Increases Brain Oxidative Stress and Enhances the Ability of 6-Hydroxydopamine to Cause Dopaminergic Degeneration in a Rat Model of Parkinson's Disease.
    Cruces-Sande A; Rodríguez-Pérez AI; Herbello-Hermelo P; Bermejo-Barrera P; Méndez-Álvarez E; Labandeira-García JL; Soto-Otero R
    Mol Neurobiol; 2019 Apr; 56(4):2845-2854. PubMed ID: 30066305
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Common Mechanisms Underlying α-Synuclein-Induced Mitochondrial Dysfunction in Parkinson's Disease.
    Sohrabi T; Mirzaei-Behbahani B; Zadali R; Pirhaghi M; Morozova-Roche LA; Meratan AA
    J Mol Biol; 2023 Jun; 435(12):167992. PubMed ID: 36736886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.